1. What it is. A free, nonclinical membership limited to 100 accepted people. Accepted members receive a Founder number, first invitation when services open in their state, and the chance to give product feedback.
2. What it isn't. It is not a medical visit, prescription, treatment plan, subscription or payment. It does not guarantee any price, discount, medication, coverage in your state, or that services will launch.
3. Eligibility. 18+, U.S. resident, verified email, one place per person and per email address. Automated or duplicate sign-ups are removed.
4. The cap and waitlist. Places are given strictly in the order the database confirms them. After 100 acceptances, new sign-ups join a first-come waitlist.
5. Pricing. Joining remains free. Illustrative proposal examples may be displayed, but are not final offers or verified medication/provider costs. Illustrative Founder pricing is a flat 40% off the proposed standard price for the same plan, term and payment cadence (Founders pay 60%). Prepaid 12/24/48/52-week totals are discounted directly, with no stacked discount. Subject to a reviewed, executed contract and available services; not a live offer or guaranteed availability. The Founder benefit is limited to the first 100 accepted Founders and is subject to a reviewed, executed contract and the services actually available. Proposed Founder pricing is not a separate membership fee or current savings. Final regular and Founder prices require executed, reviewed agreements. Any price-lock terms require verified contract review. [Review: actual costs, standard fees, lock duration and change/cancellation rules.]
6. Leaving. You may ask to leave at any time. [Review: whether released places pass to the waitlist.]
Draft pending counsel and operator review. Business details are owner-supplied, not independently verified. Items marked [Review] require verification of registration, address spelling, contact processes, governing law, partners and state scope before launch. Nothing here claims certification, licensure or regulatory approval.
Return home